Treatment of Pleural Mesothelioma: ASCO Guideline Update.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 39778125.
- Also identified by DOI 10.1200/JCO-24-02425.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To provide evidence-based recommendations to practicing physicians and others on the management of pleural mesothelioma (PM). ASCO convened an Expert Panel of medical oncology, thoracic surgery, radiation oncology, pathology, cancer genetics, and advocacy experts to conduct an updated literature search, which included systematic reviews, meta-analyses, randomized controlled trials, and prospective and retrospective comparative observational studies published from 2016 through 2024. Outcomes of interest included survival, disease-free or recurrence-free survival, and quality of life. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations. The literature search identified 110 additional relevant studies to inform the evidence base for this guideline. Evidence-based recommendations were developed for surgical cytoreduction, immunotherapy, chemotherapy, pathology, and germline testing in patients with PM.Additional information is available at www.asco.org/thoracic-cancer-guidelines.
Medical subject headings
- Pleural Neoplasms
- Mesothelioma
- Lung Neoplasms